Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. More Details
Adequate balance sheet with limited growth.
Share Price & News
How has Pulmonx's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LUNG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: Insufficient data to determine LUNG's volatility change over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: Insufficient data to determine how LUNG performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how LUNG performed against the US Market.
Long-Term Price Volatility Vs. Market
How volatile is Pulmonx's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StHave Insiders Been Buying Pulmonx Corporation (NASDAQ:LUNG) Shares?
1 month ago | Simply Wall StIs Pulmonx Corporation's (NASDAQ:LUNG) Shareholder Ownership Skewed Towards Insiders?
Is Pulmonx undervalued compared to its fair value and its price relative to the market?
Share Price vs. Fair Value
Below Fair Value: LUNG ($56.83) is trading above our estimate of fair value ($26.18)
Significantly Below Fair Value: LUNG is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: LUNG is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: LUNG is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LUNG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LUNG has negative assets, so we can't compare its PB Ratio to the US Medical Equipment industry average.
How is Pulmonx forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LUNG is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LUNG is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LUNG is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LUNG's revenue (28.9% per year) is forecast to grow faster than the US market (10.4% per year).
High Growth Revenue: LUNG's revenue (28.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LUNG's Return on Equity is forecast to be high in 3 years time
How has Pulmonx performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: LUNG is currently unprofitable.
Growing Profit Margin: LUNG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if LUNG's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare LUNG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LUNG is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (0.8%).
Return on Equity
High ROE: LUNG has a negative Return on Equity (-3887.75%), as it is currently unprofitable.
How is Pulmonx's financial position?
Financial Position Analysis
Short Term Liabilities: LUNG's short term assets ($55.6M) exceed its short term liabilities ($15.2M).
Long Term Liabilities: LUNG's short term assets ($55.6M) exceed its long term liabilities ($55.4M).
Debt to Equity History and Analysis
Debt Level: LUNG's debt to equity ratio (6627.6%) is considered high.
Reducing Debt: Insufficient data to determine if LUNG's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LUNG has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LUNG has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 20.9% each year.
What is Pulmonx current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LUNG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LUNG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LUNG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LUNG's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LUNG's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Glen French (58 yo)
Mr. Glendon E. French, also known as Glen, has been Chief Executive Officer, President and Director at Pulmonx Corporation since December 2014 and also serves as its Secretary. From January 2014 to Novembe...
CEO Compensation Analysis
Compensation vs Market: Glen's total compensation ($USD1.12M) is below average for companies of similar size in the US market ($USD3.66M).
Compensation vs Earnings: Insufficient data to compare Glen's compensation with company performance.
|CEO, President||6.17yrs||US$1.12m||3.58% |
|Chief Financial Officer||1.75yrs||US$428.90k||0.64% |
|Chief Commercial Officer||no data||US$473.31k||0.32% |
|Chief Technical Officer||1.08yrs||no data||no data|
|Vice President of Finance and Administration||no data||no data||no data|
|Vice President of Finance & Administration (U.S.)||no data||no data||no data|
|Senior VP & GM of Europe Middle-East & Africa||no data||no data||no data|
|Senior Vice President of Sales - North America||no data||no data||no data|
Experienced Management: LUNG's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
|CEO, President||6.17yrs||US$1.12m||3.58% |
|Independent Chairperson of the Board||1.33yrs||US$28.55k||0.074% |
|Independent Director||14yrs||no data||0.045% |
|Independent Director||11yrs||no data||no data|
|Independent Director||0.33yr||no data||0.074% |
|Independent Director||0.33yr||no data||no data|
|Independent Director||1.08yrs||US$26.05k||0.044% |
Experienced Board: LUNG's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: LUNG only recently listed within the past 12 months.
Pulmonx Corporation's company bio, employee growth, exchange listings and data sources
- Name: Pulmonx Corporation
- Ticker: LUNG
- Exchange: NasdaqGS
- Founded: 1995
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: US$2.027b
- Shares outstanding: 35.67m
- Website: https://pulmonx.com
Number of Employees
- Pulmonx Corporation
- 700 Chesapeake Drive
- Redwood City
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|LUNG||NasdaqGS (Nasdaq Global Select)||Yes||Common Shares||US||USD||Oct 2020|
|4NI||BST (Boerse-Stuttgart)||Yes||Common Shares||DE||EUR||Oct 2020|
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases....
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/02/28 00:42|
|End of Day Share Price||2021/02/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.